title: Outcomes, costs and cost-effectiveness of treating hepatitis C with direct acting antivirals.
abstract: Hepatitis C is a global public health burden. Long-term consequences are the development of liver cirrhosis and hepatocellular carcinoma. Introduction of different direct acting antivirals targeting the hepatitis C proteins has considerably increased rates of sustained viral response. First active substances introduced in 2011 were NS3/4A protease inhibitors telaprevir and boceprevir. In 2013/2014 the second generation of direct acting antivirals sofosbuvir, simeprevir, daclatasvir, ledipasvir and 3D therapy containing ombitasvir/paritaprevir/ritonavir and dasabuvir followed. This review focuses on treatment outcomes and costs of introduced direct acting antivirals. We provide an overview on SVR-rates in clinical trials and clinical practice, treatment costs in different countries as well as results of cost-effectiveness analyses for different treatment strategies.
authors.affiliation: Institute for Epidemiology, Social Medicine & Health Systems Research, Hannover Medical School, Carl-Neuberg-Str. 1, 30625 Hannover, Germany.
authors.forename: Jona T
authors.initials: JT
authors.lastname: Stahmeyer
authors.affiliation: Department of Internal Medicine, Krankenhaus Nordwest, Steinbacher Hohl 2-26, 60488 Frankfurt a.M., Germany.
authors.forename: Siegbert
authors.initials: S
authors.lastname: Rossol
authors.affiliation: Institute for Epidemiology, Social Medicine & Health Systems Research, Hannover Medical School, Carl-Neuberg-Str. 1, 30625 Hannover, Germany.
authors.forename: Christian
authors.initials: C
authors.lastname: Krauth
keywords: chronic hepatitis C; costs; cost–effectiveness; direct acting antivirals; effectiveness; treatment